News
Media
Conferences
Events
Partners
Publications
Resources
Biomarker Consortium
Subscribe

Your AI-Trained Oncology Knowledge Connection!

Andrew Brunner, MD

Articles by Andrew Brunner, MD

Initiating Treatment for Lower-Risk MDS With Symptomatic Anemia

ByRami Komrokji, MD,Andrew Brunner, MD,Hetty Carraway, MD,Yazan Madanat, MD,Amer Zeidan, MBBS, MHS

July 3rd 2023

The panel shares at what point they decide to start treatment for patients with lower-risk MDS and symptomatic anemia.

First-Line Treatment Options for Lower-Risk MDS With Symptomatic Anemia

ByRami Komrokji, MD,Andrew Brunner, MD,Hetty Carraway, MD,Yazan Madanat, MD,Amer Zeidan, MBBS, MHS

July 3rd 2023

Yazan Madanat, MD, details the available options for first-line treatment of patients with lower-risk MDS and symptomatic anemia.

Risk Stratification of MDS

ByRami Komrokji, MD,Andrew Brunner, MD,Hetty Carraway, MD,Yazan Madanat, MD,Amer Zeidan, MBBS, MHS

June 26th 2023

Amer Zeidan, MBBS, MHS, explains risk stratification in MDS, how the process has evolved over time, and the guidelines he typically follows.

Diagnosing Myelodysplastic Syndromes (MDS)

ByRami Komrokji, MD,Andrew Brunner, MD,Hetty Carraway, MD,Yazan Madanat, MD,Amer Zeidan, MBBS, MHS

June 26th 2023

Hetty Carraway, MD, reviews how MDS is diagnosed and the common symptoms that patients who have MDS may present with.

Trending on OncLive

FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma

PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer

Ixazomib-Containing Combinations Signal Potential for More PI-Based Regimens in R/R Multiple Myeloma

Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma

Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma